PATRUSSI LAURA | Professor page

Patrussi, L., Zhang, C. (2026). Editorial: Exploring unconventional T cells and CAR-T-cells in cancer immunotherapy. FRONTIERS IN IMMUNOLOGY, 17 [10.3389/fimmu.2026.1900363]. - view more
Tatangelo, V., Carullo, G., Lopresti, L., Ulivieri, C., Brogi, S., Butini, S., et al. (2026). Taginostat, a new quinolone-based HDAC6 inhibitor, promotes apoptosis of chronic lymphocytic leukemia cells in vitro and in vivo by activating STAT4. APOPTOSIS, 31(7) [10.1007/s10495-026-02393-0]. - view more
Cassioli, C., Capitani, N., Staton, C.C., Schirra, C., Finetti, F., Onnis, A., et al. (2025). Activation-induced thrombospondin-4 works with thrombospondin-1 to build cytotoxic supramolecular attack particles. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 122(6) [10.1073/pnas.2413866122]. - view more
Finetti, F., Zevolini, F., Migliore, L., Cianfanelli, V., Marzuoli, L., Capitani, N., et al. (2025). IFT20 regulates TFEB-dependent lytic granule biogenesis in cytotoxic T lymphocytes by orchestrating the MPR-dependent transport of granzyme B. CELL DEATH & DISEASE, 16(1) [10.1038/s41419-025-07727-5]. - view more
Rossi, S., Tatangelo, V., Dichiara, M., Butini, S., Gemma, S., Brogi, S., et al. (2024). A novel potent class I HDAC inhibitor reverses the STAT4/p66Shc apoptotic defect in B cells from chronic lymphocytic leukemia patients. BIOMÉDECINE & PHARMACOTHÉRAPIE, 174 [10.1016/j.biopha.2024.116537]. - view more